Look out, Amgen: Novartis wins second FDA biosim approval, this time for Enbrel copy


Put another tally in Novartis’ biosimilar win column. The company’s Sandoz generics unit has another FDA approval in hand, this time for its copy of Amgen’s anti-TNF blockbuster Enbrel.

On Tuesday afternoon, the Swiss drugmaker announced that regulators had given the thumbs-up to the knockoff, Erelzi, greenlighting the product in all of Enbrel’s indications--including rheumatoid arthritis, plaque psoriasis and psoriatic arthritis. With the decision, Sandoz is now one step closer to grabbing a piece of the $5.10 billion in U.S. sales that Enbrel collected last year.

The move is no surprise, given the 20-0 backing an FDA advisory committee gave the candidate last month. Although the agency doesn’t always follow panel recommendations, it typically does.

Virtual Roundtable

ESMO Post Show: Highlights from the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields. Register today.

The go-ahead puts Novartis in position to pad its lead in the U.S. biosimilars market, which it first took last September when it rolled out Zarxio, a copy of Amgen’s Neupogen. Since then, Pfizer has won U.S. regulators’ favor for its version of Johnson & Johnson’s Remicade, but that product has yet to launch.

It may still be awhile before Erelzi actually sees the market, though. This March, Amgen slapped Sandoz with a patent infringement suit, claiming the generics giant was “piggybacking on the fruits” of its “trailblazing efforts” with Enbrel and asking the U.S. District Court for the District of New Jersey to grant an injunction to block Erelzi sales.

Amgen, for one, would like to keep Sandoz at bay for as long as possible--especially with Neupogen already under attack. And meanwhile, to help fill the gap, it’s hard at work on a biosimilar program of its own. Its iteration of AbbVie best-seller Humira--dubbed ABP 501--also scored a unanimous “yes” recommendation from panel experts, picking up 26-0 victory one day before Sandoz’s unanimous Erelzi vote.

- read Novartis' release

Related Articles:
Sandoz Enbrel biosim cruises at FDA panel, endangering key Amgen sales
FDA staffers like Sandoz' biosimilarity data for copy of Amgen's Enbrel
Novartis' Sandoz aims for 5 biosim launches by 2020
Novartis finally gets to roll out inaugural biosim Zarxio. What will payers and docs do?
In unanimous vote, FDA committee backs Amgen's Humira biosim

Suggested Articles

While the failure might be a missed chance at revenue, it shouldn’t hurt Ibrance’s ability to rack up sales in the metastatic setting, one exec says.

Patients receiving Bavencio actually did worse than those who got placebo, increasing the risk of death by 31%.

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.